Biotech Investment and Deal-making are Front and Center at #BIOCEO18

Biotech Investment and Deal-making are Front and Center at #BIOCEO18

The business of making life-saving treatments is fraught with setbacks, challenges and failures. Along the way, new discoveries may pivot searches in new directions. Failures are not necessarily the end of the journey, and with each setback, new data is added to future research. Consider the recent CAR-T cell immunotherapy approvals by the FDA, ushering in a new era of exciting new medicines. These therapies have been in development for a least two decades requiring sustained infusions of cash and a solid commitment to bring concept to reality.

Because drug development is front-loaded on the research and development side, profits are not realized for many years, if at all. Biotech start-ups and publicly-held companies rely heavily on investment and/or other life sciences partners to sustain the innovation that ultimately will improve and save lives.  The United States carries much of the burden—60% of worldwide clinical programs occur in the US. These trials drive medical breakthroughs.

This coming February, BIO will host the BIO CEO & Investor Conference to facilitate drug innovation. More than 650 investors will join a host of established and emerging publicly traded and select private biotech companies to evaluate fresh investment opportunities. The event, now in its 20th year, will provide panel discussions featuring a diversity of perspectives on the latest breakthroughs, trends and developments affecting the industry, one-on-one partnering meetings to scout potential investments and deal partners and company presentations by 190 companies hand selected based on their pipeline and R&D activities.

It is an important event with tangible outcomes.  Well over half of the companies that attended the conference in 2016 have negotiated investment deals since that time.

The program for the conference is shaping up nicely with 150 investors already registered, pacing 35% ahead of 2017.  Confirmed “Fireside Chat” speakers represent veterans in the industry as well as their younger counterparts. Their insight as players in some of most notable IPOs and M&As will be invaluable to attendees. The list is below; full bios can be found here.

Deborah Dunsire, MD, President and Chief Executive Officer, XTuit Pharmaceuticals

Deborah Dunsire brings over 25 years of experience in developing and commercializing novel therapeutics across three continents. Formerly the CEO and President of Millennium Pharmaceuticals, she has worked with Johnson & Johsnon, Takeda Pharmaceuticals and Novartis. Deborah has served for many years as a board member of the Biotechnology Innovation Organization.

Lan Huang, PhD, Co-Founder, Charmain and Chief Executive Officer, BeyondSpring Pharmaceuticals

Lan Huang has more than a decade of entrepreneurial experience in the Chinese and U.S. biotechnology industry and invented and holds patents for a number of biotech products for oncology and dermatology indications. In 2009, she was the recipient of China’s “Thousand Talent Innovator Award.” BeyondSpring Pharmaceuticals conducted its IPO with Nasdaq in March 2017.

Jeffrey D. Marrazzo, Co-Founder and Chief Executive Officer, Spark Therapeutics

Jeff Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia to a fully integrated gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments.

Vivek Ramaswamy, Founder and Chief Executive Officer, Roivant Sciences

Prior to founding Roivant, Vivek Ramaswamy was an investor in the biotechnology sector. He currently serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation and he is a member of the Board of Directors of Axovant Sciences, Myovant Sciences, and Roivant Sciences. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.

Vicki Sato, PhD, Chairman, Denali Therapeutics; Chairman, Vir Biotechnology

Currently, Vicki Sato is a member of the board of directors of publicly held companies Bristol Myers Squibb Company, PerkinElmer Corporation, Borg Warner Corporation, and Syros Pharmaceuticals. She also serves as chair of the board of directors for Denali and Vir. She was also the President of Vertex Pharmaceuticals, retiring in 2005, and has taught as a professor of management practice at Harvard Business School.

Registration is open, and BIO has secured a block of hotel rooms with a conference group rate which will be available until Friday, January 26, 2018 or until the block has filled – whichever comes first. Room reservations can be made here.

Media registration is complimentary for applicants with valid press credentials.

#BIOCEO18 is possible thanks to the generous support of our sponsors.

Filed under: Events, , , ,